- Home
- GNTA vs MAIA Comparison
GNTA vs MAIA Comparison
Compare GNTA & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- MAIA
- Stock Information
- Founded
- GNTA 2014
- MAIA 2018
- Country
- GNTA Italy
- MAIA United States
- Employees
- GNTA N/A
- MAIA N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- GNTA Health Care
- MAIA Health Care
- Exchange
- GNTA Nasdaq
- MAIA Nasdaq
- Market Cap
- GNTA 67.4M
- MAIA 62.4M
- IPO Year
- GNTA 2021
- MAIA 2022
- Fundamental
- Price
- GNTA $5.34
- MAIA $2.82
- Analyst Decision
- GNTA Strong Buy
- MAIA
- Analyst Count
- GNTA 1
- MAIA 0
- Target Price
- GNTA $25.00
- MAIA N/A
- AVG Volume (30 Days)
- GNTA 28.4K
- MAIA 60.0K
- Earning Date
- GNTA 01-01-0001
- MAIA 11-05-2024
- Dividend Yield
- GNTA N/A
- MAIA N/A
- EPS Growth
- GNTA N/A
- MAIA N/A
- EPS
- GNTA N/A
- MAIA N/A
- Revenue
- GNTA N/A
- MAIA N/A
- Revenue This Year
- GNTA N/A
- MAIA N/A
- Revenue Next Year
- GNTA N/A
- MAIA N/A
- P/E Ratio
- GNTA N/A
- MAIA N/A
- Revenue Growth
- GNTA N/A
- MAIA N/A
- 52 Week Low
- GNTA $2.20
- MAIA $0.82
- 52 Week High
- GNTA $7.28
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- GNTA 56.89
- MAIA 50.98
- Support Level
- GNTA $4.89
- MAIA $2.36
- Resistance Level
- GNTA $6.20
- MAIA $2.72
- Average True Range (ATR)
- GNTA 0.70
- MAIA 0.22
- MACD
- GNTA -0.06
- MAIA 0.02
- Stochastic Oscillator
- GNTA 37.32
- MAIA 72.28
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.